An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs GDC 0349 (Primary)
- Indications Non-Hodgkin's lymphoma; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2013 Planned End Date changed from 1 Feb 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 09 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.